摘要
目的分析阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作的临床疗效。方法以2013年1月—2015年8月榆林市星元医院收治的短暂性脑缺血发作患者92例为研究对象,根据就诊病历号顺序分为观察组和对照组,每组46例,对照组给予氯吡格雷,观察组在对照组的用药基础上加用阿托伐他汀,比较两组的临床疗效、血清超敏C反应蛋白(hs-CPR)和脂蛋白相关磷脂酶A2(Lp-PLA2)水平变化等近期疗效指标,以及血脂水平、凝血功能、暂性脑缺血发作和脑梗死发生率等远期疗效及治疗期间不良反应发生情况。结果治疗后,观察组的总有效率为91.3%,显著高于对照组的73.9%;治疗后1个月,观察组和对照组的hs-CPR和Lp-PLA2水平均较治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05);治疗1年后,观察组的总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白(LDL)水平均显著低于治疗前及对照组(P<0.05),观察组和对照组的血小板计数(PLT)、凝血酶原时间(PT)、活化部分凝血酶时间(APTT)比较,差异均无统计学意义;随访1年中,观察组短暂性脑缺血发作再发率和脑梗死发生率均显著低于对照组,差异有统计学意义(P<0.05);治疗期间,两组不良反应发生率比较,差异无统计学意义。结论与单用氯吡格雷相比,阿托伐他汀联合氯吡格雷治疗短暂性脑缺血发作的近期疗效及远期疗效显著,且不增加不良反应。
Objective To investigate the clinical effect of atorvastatin combined with lopidogrel in patients with transient ischemic attack. Methods Totally 92 cases of patients with transient ischemic attack in Xingyuan Hospital of Yulin City from January 2013 to August 2015 were divided into observation group and control group, 46 cases in each group. Patients in observation group were treated with atorvastatin combined with lopidogrel, and patients in control group were treated with lopidogrel. The differences in short term effect, long-term effect, and adverse reaction between two groups were compared. Results The total effective rate of observation group was significantly higher than that of control group （P 〈 0.05）;After treatment, the levels of hs-CPR, Lp-PLA2TC, TG, and LDL, the recurrence rate of transient ischemic attack and the incidence of cerebral infarction of the observation group were significantly lower than that of the control group and before treatment （P 〈 0.05）, but the differences in PLT, PT, and APTT between two groups before and after treatment were not significant. Conelusion The clinical effect of atorvastatin combined with lopidogrel in patients with transient ischemic attack were remarkable, and the incidence of adverse events do not increase.
作者
高鹏举
王恺
GAO Peng-ju WANG Kai(Neurology Department, Xing yuan hospital ofyulin city, Yulin 719000, China)
出处
《药物评价研究》
CAS
2017年第3期361-364,共4页
Drug Evaluation Research
